The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 13, 2021

Filed:

Dec. 09, 2019
Applicant:

Nantkwest, Inc., San Diego, CA (US);

Inventors:

Hans G. Klingemann, San Diego, CA (US);

Laurent H. Boissel, San Diego, CA (US);

Nathan T. Schomer, San Diego, CA (US);

Assignee:

NantKwest, Inc., San Diego, CA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/17 (2015.01); A61P 35/00 (2006.01); C12N 15/62 (2006.01); A61P 35/02 (2006.01); C12N 15/85 (2006.01); C07K 14/705 (2006.01); A61K 9/00 (2006.01); C07K 14/82 (2006.01); C07K 14/55 (2006.01); C07K 14/725 (2006.01); C07K 14/54 (2006.01);
U.S. Cl.
CPC ...
A61K 35/17 (2013.01); A61K 9/0029 (2013.01); A61P 35/02 (2018.01); C07K 14/5443 (2013.01); C07K 14/55 (2013.01); C07K 14/7051 (2013.01); C07K 14/70553 (2013.01); C07K 14/70564 (2013.01); C07K 14/70596 (2013.01); C07K 14/82 (2013.01); C12N 15/625 (2013.01); C12N 15/85 (2013.01);
Abstract

Provided herein are modified NK-92® cells comprising one or more nucleic acids encoding i) a homing receptor, ii) Antigen Binding Protein (ABP) or Chimeric Antigen Receptor (CAR) that specifically binds to a target antigen, iii) an Fc Receptor such as CD16 or CD16-158V, and/or iv) a cytokine, wherein the nucleic acid sequence is operably linked to a promoter. Further provided herein are modified NK-92® cells comprising one or more nucleic acids encoding i) IL-12 and/or TGF-beta trap, ii) an Antigen Binding Protein (ABP) or Chimeric Antigen Receptor (CAR) that specifically binds to a target antigen, iii) an Fc Receptor such as CD16 or CD16-158V, and/or iv) a cytokine, wherein the nucleic acid sequence is operably linked to a promoter. Also provided are compositions and kits comprising the modified NK-92® cells, as well as methods of treating cancer using the modified cells.


Find Patent Forward Citations

Loading…